InvestorsHub Logo
Followers 32
Posts 5818
Boards Moderated 0
Alias Born 05/23/2006

Re: shipbuilder post# 322942

Thursday, 01/18/2018 7:22:39 PM

Thursday, January 18, 2018 7:22:39 PM

Post# of 346043
page 10

http://files.shareholder.com/downloads/PPHM/5892670337x0xS1683168-17-1772/704562/filing.pdf

Additionally, we have U.S. and foreign patents and patent applications relating more specifically to our product, bavituximab, including composition of
matter, combinations and methods of use in treating angiogenesis and cancer and in treating viral infections and diseases, alone  and in combination therapies.
These patents that more specifically concern bavituximab compositions and their use in treating cancer, both alone and in combination therapies, are currently set
to expire between 2023 and 2025.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News